Johns Hopkins School of Medicine is an educational institution that offers training in medical disciplines. It offers doctorate programs for Medicinae Doctor (M.D.) and Philosophiae Doctor (Ph. D.). In addition, it offers a biomedical engineering program. The school provides education in medical disciplines such as Anesthesiology and Critical Care Medicine, Biological Chemistry, Cell Biology, Emergency Medicine, Neuroscience, Oncology, Orthopedic Surgery, Pathology, Pediatrics, Physiology, Radiology, Surgery, and Urology. Johns Hopkins School of Medicine is based in Baltimore, Maryland. The School of Medicine is a subsidiary of the Johns Hopkins University.
720 Rutland Avenue
Baltimore, MD 21205-2196
Rockefeller, Johns Hopkins Behind Horrific Human Syphilis Experiments, Allege Guatemalan Victims in Lawsuit
Apr 1 15
Over 750 victims have sued The Rockefeller Foundation, the Johns Hopkins Hospital, the Johns Hopkins University, The Johns Hopkins University School of Medicine, the Johns Hopkins Bloomberg School of Public Health, and the Johns Hopkins Health System Corporation, alleging that they were the driving force behind human experiments in which vulnerable populations of Guatemalans were deceived and intentionally exposed to syphilis, gonorrhea and other venereal diseases and pathogens, without giving any informed consent. The experiments targeted school children, orphans, psychiatric hospital patients, prison inmates and military conscripts. The Obama Administration apologized to Guatemala for the Guatemala Experiments in 2010. The Administration tasked the Presidential Commission for the Study of Bioethical Issues to investigate the experiments. The details of the experiments were deliberately hidden from the world, and remained so until the Commission published its report in September 2011, confirming that barbaric human experiments constituting human rights violations occurred, for example: prostitutes were infected with venereal disease and then provided for sex to subjects for intentional transmission of the disease; subjects were inoculated by injection of syphilis spirochetes into the spinal fluid that bathes the brain and spinal cord, under the skin, and on mucous membranes; an emulsion containing syphilis or gonorrhea was spread under the foreskin of the penis in male subjects; the penis of male subjects was scraped or scarified and then coated with the emulsion containing syphilis or gonorrhea; a woman from the psychiatric hospital was injected with syphilis, developed skin lesions and wasting, and then had gonorrheal pus from a male subject injected into both of her eyes. Many of the Guatemalans developed venereal disease. Most were never treated. Researchers subjected the Guatemalans to repeated blood draws, lumbar punctures and cisternal punctures of the suboccipital portion of the brain, gynecological examinations, touching and penetration of sexual organs, and forced or coerced sexual contact. Key Rockefeller and Johns Hopkins researchers involved in the Guatemala Experiments, were also behind the now infamous Tuskegee experiments, in which 600 impoverished African-American sharecroppers were never informed they had syphilis, and were given placebos rather than real medicine. The researchers watched while the experiment subjects wasted away and infected their wives and children with the disease. The Tuskegee experiments were halted after being exposed by a whistleblower. The Guatemala victims have also sued Bristol-Myers Squibb, which supplied penicillin necessary for the Guatemala Experiments. The case has been filed in the Circuit Court in Baltimore City, Maryland. The victims are represented by three law firms: Meridian 361 International Law Group, PLLC of Portland, Maine; Escritorio Juridico Rodriguez Fajardo y Asociados of Caracas, Republica Bolivariana de Venezuela; and Salsbury, Clements, Bekman, Marder & Adkins of Baltimore, Maryland.
Compugen Ltd. Announces Initiation of Multi-Year Research Collaboration with Johns Hopkins School of Medicine
Dec 18 14
Compugen Ltd. announced the initiation of a multi-year research collaboration with Johns Hopkins University, School of Medicine, on evaluating immune checkpoint candidates. The project will be directed by Prof. Drew Pardoll and Dr. Charles Drake of John Hopkins. Prof. Pardoll and Dr. Drake, members of Compugen's Scientific Advisory Board, are pioneers in the field of immuno-oncology. The collaboration will focus on further evaluation of selected novel B7/CD28-like immune checkpoint candidates discovered by Compugen for the potential treatment of cancer. This evaluation will include the candidates' differentiation profile with respect to known checkpoints and their potential to serve either for monotherapy or in combination with other cancer treatments. This collaborative research will expand Compugen's ongoing assessment of the biology and mechanism of actions of its novel B7/CD28-like immune checkpoint proteins, and provide access to the world-class immuno-oncology research tools and expertise at Johns Hopkins University. The specific studies under the collaboration will assist Compugen in further substantiating the potential of its novel proteins as targets for cancer immunotherapy. It is anticipated that the results of this collaboration will significantly broaden the underlying scientific knowledge of Compugen's targets and will support their translation toward the clinic.
Johns Hopkins University School of Medicine Presents at Southeast BIO Investor & Partnering Forum, Nov-07-2013 08:30 AM
Nov 1 13
Johns Hopkins University School of Medicine Presents at Southeast BIO Investor & Partnering Forum, Nov-07-2013 08:30 AM. Venue: Jefferson Hotel, Richmond, Virginia, United States. Speakers: Elizabeth Good Mazhari.